Articles tagged with Dyslipidemia
The updated guideline consolidates evidence-based recommendations for managing dyslipidemias, offering a comprehensive approach to lower risk of atherosclerotic cardiovascular disease. The guideline recommends earlier intervention through healthy lifestyle changes and considers the use of a new cardiovascular disease risk calculator, P...
A Kyoto University study reveals the molecular mechanism of high-density lipoprotein (HDL) production. Researchers used a new imaging method to show how ATP-binding cassette protein A1 (ABCA1) generates HDL molecules, a complex process involving the transfer of lipids into the extracellular domain.
Women who experience menopause before age 50 are at higher risk of developing fatty liver disease and its related metabolic risk factors. The study found that early menopause is associated with increased risks of pre-diabetes, obesity, hypertension, and dyslipidemia.
The review explores the pathophysiological mechanisms linking obstructive sleep apnea syndrome and metabolic syndrome, highlighting recent advancements in therapeutic strategies. Treatment approaches aim to break the harmful cycle between OSA and MetS, which affects approximately 14% of the global population.
Researchers explore the connection between Alzheimer's and metabolic syndrome, finding links between insulin regulation, high blood pressure, and obesity. The study suggests that maintaining healthy blood fat levels may be crucial for brain health, paving way for potential therapeutic developments.
A recent study found that effective pediatric obesity treatment is associated with lower incidences of mortality in young adulthood. The treatment was also linked to reduced long-term morbidity, such as type 2 diabetes, dyslipidemia, and hypertension.
The review explores the pathophysiological relationship between OSA and MetS, revealing a complex cycle of increased cardiovascular risks. Treatment options, including CPAP, weight management, and metabolic surgery, are discussed for improving patient outcomes.
A new study found a 29% increase in risk for developing dyslipidemia due to COVID-19, with seniors and people with type 2 diabetes being most affected. The research suggests that tackling dyslipidemia can reduce the risk of cardiovascular disease in those who have had COVID.
A study analyzed health checkup data and found that individuals with mild dyslipidemia were less likely to seek medical follow-up compared to those with severe abnormalities. Nearly 80% of respondents did not follow up with a physician, highlighting the need for improved follow-up attendance at medical consultations.
A meta-analysis of 34 studies found a significant association between autism spectrum disorder (ASD) and increased risks of developing diabetes, dyslipidemia, and heart disease. Children with ASD were more likely to develop these metabolic complications, prompting clinicians to monitor them closely.
Research reveals obesity increases risk of diabetes and hypertension more significantly in women, with weight loss effective in reducing disease risk. However, merely losing weight is insufficient for reducing dyslipidemia in women, highlighting the need for lifestyle improvement guidance and treatment.
A systematic review and meta-analysis of 34 studies found individuals with autism have a higher associated risk of developing diabetes, dyslipidemia, and heart disease. Clinicians should monitor individuals with autism for early signs of cardiometabolic disease and its complications.
A study of 1779 adolescents found that early-life elevated lipids and dyslipidemia are linked to worsening subclinical atherosclerosis. Conversely, treatment at age 17 effectively halted progression and even reversed it. This critical evidence emphasizes the need for early-life screening and prevention.
A new comprehensive guideline, C-CHANGE, offers 83 actionable recommendations to prevent and treat cardiovascular disease in Canadian adults. The updated resource incorporates new or revised recommendations from 11 guideline groups, addressing key risk factors such as dietary habits, smoking, and physical activity.
A recent study published in the Journal of Nutritional Science found that consuming potatoes has no increased risk of cardiometabolic disorders. In fact, those who ate more potatoes also consumed more fruits and vegetables, meeting dietary guidelines recommendations.
The USPSTF recommends prescribing statins for adults aged 40-75 with one or more CVD risk factors and estimated 10-year CVD risk of 10% or greater. For those aged 76 or older, the evidence is insufficient to make a recommendation. Statin use can significantly reduce CVD events and mortality in this population.
Arterial stiffness in adolescence is a novel risk factor for hypertension, insulin resistance, and type 2 diabetes in young adulthood and mid-adulthood. Risk factors include maternal smoking habits, early life smoking patterns, high salt intake, genetic inheritance, obesity, and elevated blood pressure from childhood.
A green Mediterranean diet rich in polyphenols and low in red and processed meat may slow age-related brain atrophy. The DIRECT PLUS 18-month trial found significant attenuation of brain atrophy among participants who adhered to both diets.
Researchers found that moderate potato consumption among adolescent girls did not increase the risk of overweight or high blood pressure, and may even be associated with improved nutrient intakes. The study suggests that potatoes can be a part of a healthy diet pattern, particularly when consumed in moderation.
A new study published in CHEST finds that shortened sleep duration is independently associated with daytime sleepiness, while obstructive sleep apnea is linked to obesity, hypertension, and dyslipidemia. The study challenges traditional beliefs about the impact of sleep disorders on health.
Research found that early-life exposure to severe famine as a fetus or infant significantly increases the chance of having dyslipidemia in adulthood. The association was true for women but not men, suggesting cultural differences may play a role. Severe maternal under-nutrition during pregnancy could also contribute to the increased risk.
Research suggests removing drug use barriers to effective hep C treatment for opioid-addicted patients. The elbasvir-grazoprevir treatment showed high sustained virologic response rates in a randomized trial. In contrast, lipid screening evidence is lacking for younger adults.
A study published in JAMA Cardiology found that elevated maternal low-density lipoprotein cholesterol (LDL-C) levels before pregnancy are associated with higher LDL-C levels in adult offspring. Adults exposed to such levels have a 3.8 times higher risk of having high LDL-C levels and an adjusted level of 18 mg/dl higher.
A new class of PCSK9 antibodies has been shown to reduce mortality, lower LDL-cholesterol, and improve cardiovascular outcomes in patients with dyslipidemia. The treatment was well-tolerated and proved safe, providing a promising alternative for those who do not respond to statins.
Researchers found that job stress is associated with an altered lipid profile, leading to higher rates of 'bad' cholesterol and lower levels of 'good' cholesterol. This can increase the risk of cardiovascular disease. The study analyzed data from over 90,000 workers and found a significant link between job stress and dyslipidemia.
Scientists in Japan have discovered a compound in tomatoes that enhances fatty acid oxidation and regulates hepatic lipid metabolism. The extract, 9-oxo-octadecadienoic acid, has anti-dyslipidemic effects and can help prevent vascular diseases.
Researchers found that less than a third of treatment guidelines are based on high-quality evidence, highlighting the need for transparent grading systems. The study concludes that clinicians should be aware of this limitation and apply guideline recommendations appropriately to individual patients.
Researchers tested a new cholesterol treatment LY518674 (LY5) in two studies, but found it showed no benefits compared to fenofibrate. Both drugs raised safety concerns, particularly for kidney function.
A new study shows that ACTOS significantly improved components of diabetic dyslipidemia compared to Avandia. The results indicate that treatment with ACTOS lowered triglycerides and increased HDL-C, while improving LDL-C particle concentration and size. This is important for reducing cardiovascular risk in patients with type 2 diabetes.
A new study examined ACTOS and Avandia's lipid-altering effects in patients with type 2 diabetes. The results suggest looking beyond glycemic effects to potential lipid benefits, which could inform treatment strategies.
ACTOS therapy has favorable effects on dyslipidemia, including reductions in triglycerides and increases in HDL cholesterol. Additionally, ACTOS was found to have beneficial effects on non-HDL cholesterol and A1C levels.
The Phase III study data demonstrated a median decrease of 38 percent in LDL-C and a mean increase of up to 18.7 percent in HDL-C with Lescol XL. This reduction is clinically meaningful for coronary heart disease patients, who carry an increased risk of cardiovascular events.